1. Home
  2. NSPR vs IMUX Comparison

NSPR vs IMUX Comparison

Compare NSPR & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$1.77

Market Cap

77.5M

Sector

Health Care

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$1.11

Market Cap

75.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSPR
IMUX
Founded
2005
2016
Country
United States
United States
Employees
N/A
66
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.5M
75.2M
IPO Year
2009
2013

Fundamental Metrics

Financial Performance
Metric
NSPR
IMUX
Price
$1.77
$1.11
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$4.00
$4.25
AVG Volume (30 Days)
16.4K
4.1M
Earning Date
01-01-0001
05-29-2026
Dividend Yield
N/A
N/A
EPS Growth
7.32
38.00
EPS
N/A
N/A
Revenue
$2,310,000.00
N/A
Revenue This Year
$22.91
N/A
Revenue Next Year
$72.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.51
$0.51
52 Week High
$3.34
$1.35

Technical Indicators

Market Signals
Indicator
NSPR
IMUX
Relative Strength Index (RSI) 51.61 73.81
Support Level $1.74 $0.61
Resistance Level $2.51 $1.17
Average True Range (ATR) 0.11 0.12
MACD 0.01 0.02
Stochastic Oscillator 60.36 82.69

Price Performance

Historical Comparison
NSPR
IMUX

About NSPR InspireMD Inc.

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: